Navigation Links
For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
Date:5/20/2013

BURLINGTON, Mass., May 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life is among the areas of highest unmet need. Given the high level of subjectivity and variability of tests used to measure quality of life, interviewed thought leaders state that it is difficult to differentiate therapies based on these measures. However, available clinical data and thought leader opinion indicate that the two sales-leading COPD therapies, Boehringer Ingelheim/Pfizer's Spiriva and GlaxoSmithKline's Advair/Seretide/Adoair, offer comparable efficacy on this attribute. Phase III data indicate Novartis's indacaterol/glycopyrronium may offer greater improvement in quality of life compared with these market leaders.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Chronic Obstructive Pulmonary Disease: What Gains in Efficacy Will Be Necessary to Meet Pulmonologist and Payer Expectations for Emerging LABA/LAMAs, LABA/ICSs, and MABAs? finds that surveyed U.S. pulmonologists would prescribe indacaterol/glycopyrronium to 25 percent of their COPD patients, driven by the robust Phase III efficacy data. However, Decision Resources forecasts that indacaterol/glycopyrronium will earn a more conservative patient share, constrained in part by a late launch relative to its competitors in the United States.

"Phase III data indicate that indacaterol/glycopyrronium has a strong efficacy profile," said Decision Resources Analyst Amanda Puffer . "Thought leaders are enthusiastic about the LABA/LAMA products and expect them to provide greater efficacy compared with individual current therapies. Based on lung function data and improvements in quality of life, indacaterol/glycopyrronium has advantages over both Spiriva and Advair. But the market is expected to be crowded, so we are conservative in our expected uptake of indacaterol/glycopyrronium."

The report also finds that surveyed U.S. managed care organization (MCO) pharmacy directors are not likely to reimburse premium-priced therapies offering improvements in only dosing burden over current treatment regimens. Pharmacy directors are highly willing to grant favorable formulary status to therapies that provide advantages for lung function or frequency of exacerbations over currently available therapies. However, they also indicate that if the drugs are priced at a premium to Spiriva, gains in efficacy will need to be substantial to secure reimbursement.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
3. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
4. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
5. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
7. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
8. Remote Patient Monitoring Devices Market to 2017 - Chronic Disease Prevalence and Government Curbs on Hospital Spending to Drive the Market
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):